Treatment of wounds with pharmacologic doses of the BB homodimeric form of recombinant PDGF (rPDGF-BB) induces the recruitment, activation, and proliferation of mesenchymal cells, resulting in the deposition of provisional, and subsequently collagen-containing extracellular matrix.
Introduction
Treatment of wounds with pharmacologic doses of the BB homodimeric form of recombinant PDGF (rPDGF-BB) induces the recruitment, activation, and proliferation of mesenchymal cells, resulting in the deposition of provisional, and subsequently collagen-containing extracellular matrix.
In preliminary experiments with an in vitro growth chamber model in the rat consisting of a silicone shell containing a dissected femoral vascular bundle, we found that rPDGF-BB incorporated into a rapidly dissolving collagen type I film induces the generation of a marked, but transient amount of de novo tissue around the femoral vascular bundle. In the present studies, the new tissue generated around the femoral vascular bundle was wrapped with a full thickness syngeneic skin graft to determine if functional support of the graft would lead to sustained maintenance of the underlying generated tissue and create an epithelialized soft tissue appendage. The tissue generated after a single application of rPDGF-BB was skin grafted on the 10th day, exteriorized 20 d later, and observed for an additional month. This led to the formation of soft tissue appendages which demonstrated marked neovascularization, fibroblast migration and proliferation, and increased glycosaminoglycan, fibronectin, and collagen fibril deposition, now leading to preservation of the newly generated tissue. In contrast, minimal new tissue was generated in control-treated vascular bundles or bundles treated with inactive PDGF-BB, and grafting with skin failed to sustain the underlying tissue. Thus, rPDGF-BB coupled with skin grafting induced the formation of functional large soft tissue appendages which are potentially useful clinically to fill tissue defects or to serve as a cell delivery system for transfected genes. (J. Clin. Invest. 1994 . 94:1757-1763.) Key words: angiogenesis * extracellular matrix * cell proliferation * fibroblasts * gene therapy Several growth factors have been identified which stimulate cell proliferation and extracellular matrix production. Plateletderived growth factor (PDGF) induces fibroblasts and smooth muscle cells to migrate and proliferate (1) (2) (3) (4) , and it is synthesized by, and stimulates mesenchymally derived cells and endothelial cells (5) (6) (7) (8) . In addition, PDGF is a potent chemotactic agent for monocytes (9, 10) . PDGF is comprised of two polypeptide chains, A and B, and has been identified in platelets and other cell types as AA or BB homodimers, or AB heterodimers (7, 8) . PDGF-BB binds to PDGF-a and -,/ receptors, while PDGF-AA and PDGF-AB preferentially bind PDGF-a receptors. The presence of specific receptors having distinct intracellular signaling pathways, coupled with synthesis of specific PDGF isoforms which function in an autocrine or paracrine fashion, result in unique biological effects on different cell types and tissues. For instance, the a receptor appears to mediate developmental programs, while the /3 receptor may be required for chemotaxis and cell transformation (11) (12) (13) (14) .
In vivo, recombinant (r)PDGF-BB' has been shown to influence normal and deficient soft tissue repair in both animals (10, (15) (16) (17) and humans (18, 19) . We have previously found that rPDGF-BB accelerates normal dermal repair, augmenting the acute inflammatory, provisional extracellular matrix deposition, and collagen deposition phases of wound healing (20, 21) . Since rPDGF-AA was less effective (unpublished observation), and other growth factors such as basic fibroblast growth factor and transforming growth factor-/3 1 (TGF-31 ) actually alter the normal repair process (21) , we sought to determine if rPDGF-BB could induce physiologic quantities of granulation tissue de novo. In an in vivo tissue growth chamber model consisting of an isolated arterio-venous vascular bundle within a silicone mold, rPDGF-BB bound to a collagen matrix was able to induce the formation of a sizable volume of tissue (22) . However, without continuous exogenous supply of rPDGF-BB, the new tissue completely regressed within 30 d. To render this generated tissue useful for clinical reconstructions, a means of stabilizing it and preventing cell death and matrix degradation is necessary. In this study, the growth response to rPDGF-BB is delineated, and the long term fate of this generated tissue is evaluated after it is given the functional role of supporting the perfusion and survival of a skin graft.
Methods
Preparation of rPDGF-BB. PDGF-B monomer 119 amino acids in length was purified to homogeneity and refolded and dimerized from E. coli by conventional methods, as described (21) . All rPDGF-BB used was free of detectable endotoxin. Collagen disks were prepared as described (22) (22) . Care was taken to trim the maximum amount of skeletal muscle away from each isolated vascular bundle. A small amount of muscle remained attached to all vascular bundles. Collagen film disks with or without (control) rPDGF-BB were sandwiched around the vascular bundle and the chamber was closed (see Fig. 1 A) . Chambers were then implanted into the peritoneal cavity. Chambers were exteriorized, removed, and the vascular bundles were assessed for cell proliferation and cellularity/new tissue volume at 7 or 10 d, respectively. Additional groups of animals had their vascular bundles harvested from 5-30 d after surgery to assess the time course of new tissue generation. In subsequent experiments, after 10 d the isolated tissue was wrapped in a full thickness skin graft obtained from the back of syngeneic animals (see Fig. 1 B) . The composite was placed back subcutaneously into the groin surrounded by silicone sheets (Dow Coming) to separate it from the wound margins for 20 d. One month after the first surgery the epithelialized soft tissue appendages were exteriorized and observed for an additional month. At that time, animals were sacrificed and the tissues were analyzed.
Tissue processing, histochemistry, and quantitation ofmatrix deposition. All tissues were fixed with 10% neutral buffered formalin. After fixation tissues were cross-sectioned and processed routinely for paraffin sectioning. Masson's trichrome, Alcian blue, pH 2.5, and Sirius red staining were performed as previously described (21) . The determination of Alcian blue and Sirius red positive areas were performed by image analysis with a Quantimet 520 (Leica, Deerfield, IL) computerized image analysis system connected to a Nikon FXA microscope (Nikon, Torrance, CA). Images were captured using an Optronics Engineering VI-470 CCD video camera with low light level capability (Optronics Engineering, Goleta, CA). Alcian blue slides were imaged using a 621-nm narrow band pass filter (Oriel, Stratford, CT) while Sirius red was imaged through crossed polarizers (Nikon) (21) .
Morphometric analyses. Cell counting was performed on histologic cross sections of the generated tissue using a digital image analysis system linked to morphometry software (Leco 2005; Leco Co., St. Joseph, MO). Each cross section was gray scale digitized (8 bit, 256 gray levels) at a calibration of 0.125 pm/pixel. Fibroblasts 
Results
In adult rats, the femoral artery and its venae comitans were isolated and placed within a silicone chamber (Fig. 1 A) . 10 d later, in the presence of 250 ,ug of rPDGF-BB, a large volume of tissue is generated compared with control, (177±22.5 mm3
[SEM] vs. 41±11 mm3, P < 0.0001) (Fig. 2 A) . Cell counts also revealed a dramatic associated increase in cell numbers 7 and 10 d after implantation (7 d 6 .7±2 x 106, P < 0.001) (Fig. 2 B) . However, after 30 d, the tissue was noted to undergo cell death, with reduction seen in both cell counts and tissue volume. Inactive rPDGF-BB failed to induce tissue growth, demonstrating the specific requirement for functional ligandreceptor binding to initiate signal transduction.
To quantitate cell proliferation, animals were given BrdU 7 d after implantation in the growth chamber. The BrdU positive cells were counted from the histologic sections using computerized image analysis and the total number of cells were reconstituted from volumetric analysis. rPDGF-BB treatment yielded 26,700±7,300 (SEM) proliferating cells, whereas control wafers had 5,600±1,100 proliferating cells (P < 0.001). Furthermore, during this period of tissue generation, proliferation was concentrated in a band of fibroblasts migrating towards the periphery of the new tissue) (Fig. 3, A-D) . The infiltration of new cells and deposition of matrix within and surrounding the vascular bundle is clearly observed in the rPDGF-BB-treated tissue (Fig. 3 A) whereas the skeletal muscle remains undisturbed in the control (Fig. 3 B) . The rPDGF-BB-treated group showed markedly increased staining for cellular fibronectin throughout the generated tissue on day 7 compared with controls ( Fig. 3, E and F) . This suggests that fibroblasts in the rPDGF-BB-treated group are capable of synthesizing fibronectin, a critical provisional matrix component which permits cellular migration and provides the lattice for subsequent collagen deposition (26) .
It was hypothesized that if the generated tissue was given a vital function, such as the role of providing vascular and structural support for the survival of ischemic tissue, then the tissue regression observed by 30 d might be prevented. Using the same model, the generated tissue was removed from the silicone mold at 10 d when the amount generated was maximal, and a full-thickness syngeneic skin graft was wrapped around the tissue (Fig. 1 B) . The composite was placed back subcutaneously in the groin surrounded by silicone sheets to separate it from the wound margins. After an additional 20 d, the epithelialized soft tissue appendages were exteriorized and observed for an additional month.
At the time of exteriorization, the extracellular matrix deposited in the rPDGF-BB-treated appendages underwent normal maturation with the initial deposition of a provisional matrix. The area of new tissue, and areas of both GAG and collagen content were increased approximately twofold in the rPDGF-BB-treated pedicles (Fig. 4, A and B) . If left alone, without supplemental growth factors and without skin grafting, the new tissue would have regressed completely by this time (22) . However, after skin grafting, the tissue generated shows evidence of increased glycosaminoglycan deposition (Fig. 5, A and B) , and collagen maturation and remodeling, which persisted for the duration of the experiment (Fig. 5, C and D) . rPDGF-BB-treated neotissue contains considerably greater numbers of activated fibroblasts and neovessels than controls (Fig. 5 , E and F). After exteriorization for 1 mo, the volume of tissue generated by the rPDGF-BB-treated pedicle was found to be substan- tially greater than in controls (Fig. 6, A and B; and Fig. 7 ). An accompanying marked increase in microvascular development 1E1 Con"I | was also evident, as assessed by microangiography (Fig. 6 , C rPDGFBB | and D). Numerous functional neovessels arborized from the original vascular pedicle in the rPDGF-BB-treated animals in contrast to controls. A small number of animals were carried out to three months postinitial surgery: control pedicles had necrotic lesions and further regression, in contrast to rPDGF-BB-treated pedicles (unpublished observation).
Discussion rPDGF-BB has been reported to augment new granulation tissue in animals and in patients with chronic pressure ulcers (10, (15) (16) (17) (18) (19) . However, the present results suggest rPDGF-BB can induce new tissue de novo, presumably via the recruitment of highly proliferative mesenchymal progenitor cells which are present within the vascular bundle, and associated endothelial and smooth muscle cells to provide a rich neovascular response. These findings indicate that rapid generation of de novo mesenchymal tissue growth can be induced by rPDGF-BB. Un \ , l , ' e A ' . . f ; ; ; J . @ , ' , e . . * , . BB-treated tissue was skin grafted at day 10 (present study).
In a calvarial defect model in rats, rPDGF-BB delivered once in a similar collagen vehicle also induced the transient accumulation of new soft tissue overlying the cranium (23), consistent with our earlier findings (22 forming growth factor-a, which can stimulate mesenchymal cells, such as fibroblasts and smooth muscle cells (28, 29) . In turn, fibroblasts are a rich source of both mesenchymal growth factors (e.g., PDGF, heparin-binding epidermal growth factor [30, 31] , TGF-/i), and keratinocyte growth factors (e.g., keratinocyte growth factor, (24, 32, 33) which can sustain the skin graft. Although our analysis of the skin-grafted appendages was carried out for only 1 mo after exteriorization (50 d total duration), the observed deposition of collagen fibrils upon the provisional matrix framework of glycosaminoglycans and fibronectin when appendages were exteriorized suggests this new tissue will persist. Initial treatment of the vascular bundle with rPDGF-BB is required for growth and persistence of the skin grafted appendage. Longer term experiments will be required to more fully assess whether this appendage will more closely resemble mature granulation tissue (scar) or normal skin (regeneration).
Thus, sustained, functional soft tissue appendages can be generated by skin grafting of the massive de novo tissue growth Total volume that follows a single application of human rPDGF-BB. Since mature human and rat PDGF-BB are 88% homologous at the amino acid level, and human PDGF-BB is fully active on rodent cell lines and in rodent models, human PDGF-BB would be fully expected to produce results similar to those reported here in a human system. This ability to control the fate of soft tissue generated with rPDGF-BB may have useful clinical applications. In particular, this unique approach potentially could be used to fill large soft tissue defects in individuals with chronic dermal ulcers, or other large defects in situations where full or partial thickness skin grafts are not feasible. In addition, a longlasting self-sustaining tissue appendage may be useful as a gene therapy delivery vehicle after in situ transfection of fibroblasts, endothelial cells, or keratinocytes with a relevant vector-gene combination. Its fibroblast density, vascularity, and presence of keratinocytes would permit not only localized delivery of an exogenous gene, but would also provide an added measure of safety not presently available in gene therapy clinical trials, since the tissue appendage could be easily removed.
